Lipid-lowering effect of tenofovir in HIV-infected patients.

作者信息

Fabbiani Massimiliano, Bracciale Laura, Doino Maria, Sidella Letizia, Farina Salvatore, Di Cristo Valentina, Cauda Roberto, De Luca Andrea, Di Giambenedetto Simona

出版信息

J Antimicrob Chemother. 2011 Mar;66(3):682-3. doi: 10.1093/jac/dkq464. Epub 2010 Dec 5.

DOI:10.1093/jac/dkq464

PMID:21131692

Abstract

摘要

相似文献

Lipid-lowering effect of tenofovir in HIV-infected patients.

J Antimicrob Chemother. 2011 Mar;66(3):682-3. doi: 10.1093/jac/dkq464. Epub 2010 Dec 5.

Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.初治的HIV感染患者接受每日一次替诺福韦-恩曲他滨加每日两次奈韦拉平抗逆转录病毒治疗时早期病毒学失败的风险。

Clin Infect Dis. 2008 Apr 1;46(7):1127-9. doi: 10.1086/529394.

Pre-exposure prophylaxis effective.暴露前预防有效。

AIDS Patient Care STDS. 2006 Sep;20(9):660.

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.在HIV-1感染受试者中，沙奎那韦硬胶囊/利托那韦（每日两次，每次1000/100毫克）与富马酸替诺福韦二吡呋酯联用时的药代动力学。

Br J Clin Pharmacol. 2005 Jan;59(1):38-42. doi: 10.1111/j.1365-2125.2004.02240.x.

Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.替诺福韦/恩曲他滨加奈韦拉平治疗 HIV 感染患者的安全性和有效性。

AIDS. 2010 Mar 13;24(5):777-9. doi: 10.1097/QAD.0b013e3283322895.

K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.在替诺福韦酯临床试验中，C亚型HIV-1感染患者中K65R的演变情况。

AIDS. 2007 Jan 11;21(2):265-6. doi: 10.1097/QAD.0b013e32801199ee.

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.含替诺福韦的抗逆转录病毒疗法对人类免疫缺陷病毒合并感染队列中慢性乙型肝炎的影响。

J Antimicrob Chemother. 2005 Dec;56(6):1087-93. doi: 10.1093/jac/dki396. Epub 2005 Nov 3.

Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.替诺福韦减量对一名基线存在K65R和M184V突变患者的HIV血浆病毒血症、CD4+ T细胞计数及耐药性的影响

Antivir Ther. 2008;13(5):735-7.

[First line therapy. Tenofovir DF/emtricitabine--the potent backbone].[一线治疗。替诺福韦酯/恩曲他滨——强效基础用药]

MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:12-4.

Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.由替诺福韦、恩曲他滨或拉米夫定与奈韦拉平组成的抗逆转录病毒联合疗法。

Clin Infect Dis. 2008 Oct 1;47(7):984-5. doi: 10.1086/591802.

引用本文的文献

Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B.富马酸替诺福韦艾拉酚胺酯对慢性乙型肝炎患者血脂谱的影响。

Virol J. 2024 Sep 28;21(1):234. doi: 10.1186/s12985-024-02515-7.

The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou.湖州市不同抗逆转录病毒方案治疗的 HIV 感染者血脂异常的风险。

PLoS One. 2024 Sep 20;19(9):e0305461. doi: 10.1371/journal.pone.0305461. eCollection 2024.

Interaction between antiretroviral therapy regimens and body mass index on triglyceride levels in people living with HIV: a cross-sectional and longitudinal study.抗逆转录病毒疗法方案与身体质量指数对 HIV 感染者甘油三酯水平的相互影响：一项横断面和纵向研究。

Lipids Health Dis. 2024 Jul 30;23(1):232. doi: 10.1186/s12944-024-02224-8.

Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review.联合抗逆转录病毒疗法对成年 HIV 感染者代谢综合征组分的影响：文献综述。

Viruses. 2022 Jan 11;14(1):122. doi: 10.3390/v14010122.

Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?整合酶抑制剂与替诺福韦艾拉酚胺导致的体重过度增加：机制是什么，这重要吗？

Open Forum Infect Dis. 2021 Nov 17;8(12):ofab542. doi: 10.1093/ofid/ofab542. eCollection 2021 Dec.

Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.真实世界中单中心比较恩替卡韦、富马酸替诺福韦二吡呋酯和替诺福韦艾拉酚胺在慢性乙型肝炎患者中的安全性和疗效。

Intervirology. 2022;65(2):94-103. doi: 10.1159/000519440. Epub 2021 Nov 3.

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.转换为替诺福韦艾拉酚胺/恩曲他滨/利匹韦林、替诺福韦艾拉酚胺/恩曲他滨/埃替拉韦/考比司他以及阿巴卡韦/拉米夫定/多替拉韦对HIV感染者心血管风险和血脂谱的影响：一项回顾性队列研究

BMC Infect Dis. 2021 Jun 22;21(1):595. doi: 10.1186/s12879-021-06304-3.

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯的动脉粥样硬化性心血管疾病风险概况

Open Forum Infect Dis. 2019 Nov 11;7(1):ofz472. doi: 10.1093/ofid/ofz472. eCollection 2020 Jan.

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.从含蛋白酶抑制剂（PI）方案转换为含整合酶抑制剂（INI）方案后的疗效持久性：一项针对有药物治疗经验的HIV感染受试者的单中心队列研究

Drug Des Devel Ther. 2019 Jul 9;13:2271-2282. doi: 10.2147/DDDT.S204415. eCollection 2019.

Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.在病毒学抑制的人类免疫缺陷病毒感染患者中，从抗逆转录病毒药物替诺福韦酯/恩曲他滨转换为硫酸阿巴卡韦/拉米夫定后脂质浓度的评估。

Intern Med. 2016;55(23):3435-3440. doi: 10.2169/internalmedicine.55.7518. Epub 2016 Dec 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验